• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharmaceutical Executive, September 2020 Issue (PDF)

Publication
Article
Pharmaceutical ExecutivePharmaceutical Executive-09-01-2020
Volume 40
Issue 9

Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.

Download Issue PDF
Articles in this issue
Our Launch-Time Menu
Our Launch-Time Menu
Drug Launch: Winning the Evidence Battle
Drug Launch: Winning the Evidence Battle
COVID Causes Pharma Marketers to Watch TV
Succession Plan: Skyrizi
Succession Plan: Skyrizi
New Standards for First-to-Launch Players
(O)mega Opportunity: Vascepa
(O)mega Opportunity: Vascepa
Educational Mission: Oxbryta
Educational Mission: Oxbryta
First in Class: Spravato
First in Class: Spravato
One Time for Lifetime: Zolgensma
One Time for Lifetime: Zolgensma
Biopharma Capital Markets Sizzle in 2020
Biopharma Capital Markets Sizzle in 2020
Key Support for Rare Disease Medicine Scheme
Key Support for Rare Disease Medicine Scheme
FDA in Hot Seat on ‘Buy American’ Drug Policy
FDA in Hot Seat on ‘Buy American’ Drug Policy
Unlocked Potential — ‘Keying’ in On New-Era Engagement
Unlocked Potential — ‘Keying’ in On New-Era Engagement
Vaccine Supply: Trusting in Blockchain
Vaccine Supply: Trusting in Blockchain
The Importance of Embracing Diversity
The Importance of Embracing Diversity
Recent Videos
Related Content
Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications

Biden-Harris Administration Proposes Expansion to Medicare and Medicaid to Include Anti-Obesity Medications

Don Tracy, Associate Editor
November 26th 2024
Article

The proposal aims to reduce out-of-pocket costs for a number of anti-obesity medications by 95%.

Key Findings of the NIAGARA and HIMALAYA Trials

Key Findings of the NIAGARA and HIMALAYA Trials

Don Tracy, Associate Editor
November 8th 2024
Podcast

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.

Pharma Pulse 11/26/24: RFID Technological Obstacles, Self-Care for the Flu & more

Pharma Pulse 11/26/24: RFID Technological Obstacles, Self-Care for the Flu & more

Miranda Schmalfuhs
November 26th 2024
Article

The latest news for pharma industry insiders.

Fake Weight Loss Drugs: Growing Threat to Consumer Health

Fake Weight Loss Drugs: Growing Threat to Consumer Health

Miranda Schmalfuhs
October 25th 2024
Podcast

In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.

2024 Pharmaceutical Executive APEX Award Winners

2024 Pharmaceutical Executive APEX Award Winners

Don Tracy, Associate Editor
November 25th 2024
Article
FDA Expands Labelling for Roche’s Pathway Rabbit Monoclonal Primary Antibody in Patients with Biliary Tract Cancer

FDA Expands Labelling for Roche’s Pathway Rabbit Monoclonal Primary Antibody in Patients with Biliary Tract Cancer

Don Tracy, Associate Editor
November 25th 2024
Article

Pathway is now the first and only FDA-approved companion diagnostic for identifying HER2-positive biliary tract cancer patients eligible for treatment with Ziihera.